A Phase 1 Study of IM-1021 in Participants With Advanced Cancer (NCT06823167)

🧪 Interventions in This Study

• IM-1021 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• City Of Hope — Duarte, California
• University of California — Los Angeles, California
• Colorado Blood Cancer Institute — Denver, Colorado
• Yale University Medical Center — New Haven, Connecticut
• Tampa General Hospital — Tampa, Florida
• Emory Winship Cancer Institute — Atlanta, Georgia
• University of Iowa — Iowa City, Iowa
• Norton Cancer Institute — Louisville, Kentucky
• University of Michigan — Ann Arbor, Michigan
• START Midwest — Grand Rapids, Michigan
• University of Nebraska Medical Center — Omaha, Nebraska
• Levine Cancer Institute — Charlotte, North Carolina
• Gabrail Cancer Center — Canton, Ohio
• Brown University — Providence, Rhode Island
• Sarah Cannon Research Institute - Oncology Partners — Nashville, Tennessee
• MD Anderson Cancer Center — Houston, Texas
• NEXT Oncology — Irving, Texas
• UT San Antonio Mays Cancer — San Antonio, Texas
• University of Virginia — Charlottesville, Virginia
• Copenhagen University Hospital — Copenhagen,
• Centre Leon-Berard — Lyon,
• LITO, Institut Curie Hospital Gropu — Paris,
• Gustave Roussy — Villejuif,
• START - Fundacion Jimenez Diaz — Madrid,

📞 Contact the Study Coordinator

Phone: (425) 939-7410

Email: info@immunome.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Malignancies

• Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens — Calgary, Alberta
• A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer — Palo Alto, California
• A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies — Dallas, Texas

Explore by condition: All Solid Malignancies clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.